Cat. No.: HY-101481

Flurbiprofen axetil

Customer Review

Based on 1 Customer Validation

Flurbiprofen axetil is a non-selective COX inhibitor and a nonsteroidal anti-inflammatory agent with anti-inflammatory and analgesic effects. Flurbiprofen axetil inhibits basal-like breast cancer metastasis by inhibiting the MEK/ERK signaling pathway. Flurbiprofen axetil can promote neuroprotection after focal cerebral ischemia in rats by partially activating PPAR-γ. Flurbiprofen axetil alleviates cerebral ischemia/reperfusion injury by reducing inflammation in a transient global cerebral ischemia/reperfusion rat model. Flurbiprofen axetil can alleviate inflammatory responses and cognitive function in a mild cognitive impairment (MCI) SD rat model through the AMPKα/NF-κB signaling pathway.

For research use only. We do not sell to patients.

Purity: 99.34%
CAS No.: 91503-79-6
Formula: C₁₉H₁₉FO₄
Molecular Weight:330.35

Storage:

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Flurbiprofen axetil Chemical Structure

CAS No.: 91503-79-6

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

COX

All COX Isoforms :

All MEK Isoforms :

All ERK Isoforms :

All PPAR Isoforms :

All AMPK Isoforms :

All NF-κB Isoforms :

All Interleukin Related Isoforms :

All TNF Receptor Isoforms :

All STAT Isoforms :

All Wnt Isoforms :

In Vitro

Flurbiprofen axetil (0-160 nM, 1-6 days) does not affect the proliferation and activity, but inhibits migration and invasion in BT-549 and MDA-MB-231 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Migration Assay ^[2]

Cell Line:

BT-549 and MDA-MB-231 cells
Concentration:

0 nM, 40 nM, 80 nM, 160 nM
Incubation Time:

24 h
Result:

Inhibited the migration and invasion, and 80 nM was the most appropriate concentration to use.

In Vivo

Flurbiprofen axetil (0.1 g/100 mL, drops into the eyes, 2 times/day, 24 h) has anti-inflammation effect in endotoxin-induced uveitis (EIU) rabbit model^[1].
Flurbiprofen axetil (10 mg/kg, i.p., once every two days, 28 days) inhibits breast cancer metastasis via inhibiting MEK/ERK signaling pathway in nude mice model^[2].
Flurbiprofen axetil (10 mg/kg, i.v., once) could promote a neuroprotective effect by, or in part, activation of PPAR-γ after focal cerebral ischemia in rat^[3].
Flurbiprofen axetil (5-10 mg/kg, i.v., once) protects the brain from cerebral I/R injury through reducing inflammation and brain edema in global cerebral ischemia male SD rat^[4].
Flurbiprofen axetil (10 mg/kg, i.v., once) can reduce the inflammatory response and cognitive function through the AMPKα/NF-κB signaling pathway.in formalin-induced MCI SD rat model^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

EIU rabbit model ^[1]
Dosage:

0.1 g/100 mL
Administration:

drops into the eyes, 2 times/day, 24 h
Result:

Reduce inflammatory response and leukocyte counts and PGE2 levels, reduce iris and retinal disorder and inflammatory cell infiltration.

Animal Model:

Breast cancer metastasis (1 × 10⁶ MDA-MB-231-luc cells/100 µL, i.v.) nude mice (Female Balb/c, 6 weeks) model^[2]
Dosage:

10 mg/kg
Administration:

i.p., once every two days, 28 days
Result:

Inhibited the expression of CD44 and VCAM-1, inhibited the metastasis. Inhibited the expression levels of key EMT markers (particularly N-cadherin and vimentin) without affecting proteins involved in the PI3K/AKT signaling pathway, Wnt/β-catenin signaling pathway, Janus kinase/STAT3 signaling pathway, and transforming growth factor-β/Smad signaling pathway. Inhibited the phosphorylation of MEK/ERK signaling pathway proteins and ERK phosphorylation.

Animal Model:

tMCAO male SD rat (8-12 weeks old, 280-320 g)^[3]
Dosage:

10 mg/kg
Administration:

i.v., once
Result:

Reduced neurological deficit score, reduced infarct volume percentage.

Animal Model:

Global cerebral ischemia male SD rat (300-350 g) model^[3]
Dosage:

5 mg/kg, 10 mg/kg
Administration:

i.v., once
Result:

Reduced neurological deficit score. Reduced cerebral I/R-induced neuronal damage, reduced cell apoptosis, TUNEL positive cells, cleaved caspase-3 protein expression. Reduces AQP4 and AQP9 mRNA expressions, reduces TXB2 and TXB2/6-keto-PGF1α in discrete cortex. Decreases cerebral I/R-induced inflammation in hippocampus, reduced serum TNF-α, IL-1β and ICAM-1 and NF-κB mRNA expressions.

Animal Model:

Formalin-induced MCI SD rat (male, 250-300 g, 16-17 weeks old) model^[3]
Dosage:

10 mg/kg
Administration:

i.v., once
Result:

Relieved inflammatory pain induced by formalin injection, alleviated the effect on the cognitive function, reduced the effect on neuronal damage, decreased levels of TNF-α and IL-6 in the hippocampus. Inhibited NF-κB p65 by activating AMPKα.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 91503-79-6
Appearance Oil
Molecular Weight 330.35
Formula C₁₉H₁₉FO₄
Color Colorless to off-white
SMILES

O=C(OC(OC(C)=O)C)C(C)C1=CC=C(C2=CC=CC=C2)C(F)=C1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility

In Vitro:

DMSO : 250 mg/mL (756.77 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.0271 mL

15.1355 mL

30.2709 mL

5 mM

0.6054 mL

3.0271 mL

6.0542 mL

10 mM

0.3027 mL

1.5135 mL

3.0271 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Shen J, et al. Novel NSAIDs ophthalmic formulation: flurbiprofen axetil emulsion with low irritancy and improved anti-inflammation effect. Int J Pharm. 2011 Jun 30;412(1-2):115-22. [Content Brief]

[2]. Zhu Y, et al. Flurbiprofen axetil is involved in basal-like breast cancer metastasis via suppressing the MEK/ERK signaling pathway. Cell Biol Int. 2025 Jan;49(1):68-78. [Content Brief]

[3]. Liu JL, et al. Flurbiprofen axetil promotes neuroprotection by activation of cerebral peroxisome proliferator-activated receptor gamma after focal cerebral ischemia in rats. Chin Med J (Engl). 2012 Oct;125(20):3719-24. [Content Brief]

[4]. Wu H, et al. Flurbiprofen axetil attenuates cerebral ischemia/reperfusion injury by reducing inflammation in a rat model of transient global cerebral ischemia/reperfusion. Biosci Rep. 2018 Jul 6;38(4):BSR20171562. [Content Brief]

[5]. Huang L, et al. Flurbiprofen axetil alleviates the effect of formalin-induced inflammatory pain on the cognitive function of rats with mild cognitive impairment through the AMPKα/NF-κB signaling pathway. Ann Transl Med. 2022 Nov;10(22):1210. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.0271 mL	15.1355 mL	30.2709 mL	75.6773 mL
	5 mM	0.6054 mL	3.0271 mL	6.0542 mL	15.1355 mL
	10 mM	0.3027 mL	1.5135 mL	3.0271 mL	7.5677 mL
	15 mM	0.2018 mL	1.0090 mL	2.0181 mL	5.0452 mL
	20 mM	0.1514 mL	0.7568 mL	1.5135 mL	3.7839 mL
	25 mM	0.1211 mL	0.6054 mL	1.2108 mL	3.0271 mL
	30 mM	0.1009 mL	0.5045 mL	1.0090 mL	2.5226 mL
	40 mM	0.0757 mL	0.3784 mL	0.7568 mL	1.8919 mL
	50 mM	0.0605 mL	0.3027 mL	0.6054 mL	1.5135 mL
	60 mM	0.0505 mL	0.2523 mL	0.5045 mL	1.2613 mL
	80 mM	0.0378 mL	0.1892 mL	0.3784 mL	0.9460 mL
	100 mM	0.0303 mL	0.1514 mL	0.3027 mL	0.7568 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Flurbiprofen axetil

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

NMPA-Approved Drug Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

FDA Approved & Pharmacopeial Drug Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Lipid Metabolism Compound Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Antidepressant Compound Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Nuclear Receptor Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Off-patent Drug Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cytokine Inhibitors Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Extracellular Vesicles (EVs) Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

FDA Kinase Inhibitor Library

Lactylation Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Wnt/Hedgehog/Notch Compound Library

FDA-Approved Drug Library